What is the current Hodgkin Lymphoma Treatment market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Hodgkin Lymphoma Treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Hodgkin Lymphoma Treatment market?

Increasing incidence of Hodgkin lymphoma and advancements in treatment options drive the market.

What are the major challenges facing the Hodgkin Lymphoma Treatment market?

High treatment costs and limited access to healthcare in developing regions are major challenges.

Which regions are the leaders in the Hodgkin Lymphoma Treatment market?

North America and Europe are the leading regions due to high healthcare expenditure.

Who are the top companies in the Hodgkin Lymphoma Treatment market?

Top companies include Merck, Pfizer, and Bristol Myers Squibb, offering innovative treatments.

What are the future opportunities in the Hodgkin Lymphoma Treatment market?

Emerging markets and increasing adoption of immunotherapy offer future growth opportunities.

How does technology impact the Hodgkin Lymphoma Treatment market?

Advances in technology improve diagnosis and treatment, enhancing patient outcomes and market growth.

What is the current regulatory landscape for the Hodgkin Lymphoma Treatment market?

Regulatory bodies like FDA and EMA play a crucial role in approving new treatments and ensuring safety.

What is the future outlook for the Hodgkin Lymphoma Treatment market size?

The market size is expected to reach USD 2.5 billion by 2033, driven by increasing demand.

Hodgkin Lymphoma Treatment Industry Trends & Competitive Analysis 2033

Hodgkin Lymphoma Treatment by Type (/> Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), by Application (/> Hospital, Clinic, Research Center), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Hodgkin Lymphoma Treatment Market Size | CAGR 10.2 Forecast 2033

Hodgkin Lymphoma Treatment Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hodgkin Lymphoma Treatment Market Overview

The Hodgkin Lymphoma Treatment market refers to the industry focused on developing and marketing treatments for Hodgkin lymphoma, a type of cancer that affects the immune system. As the Hodgkin Lymphoma Treatment market size is expected to grow significantly, the growth outlook and market forecast are of great interest to industry stakeholders. The Hodgkin Lymphoma Treatment market is poised for industry expansion, driven by advancements in medical technology and increasing awareness about the disease. With a current market size of approximately $3.8 billion, the industry is expected to witness a CAGR of around 8-10% during the forecast period, driven by macro drivers such as rising healthcare expenditure and an increasing patient population.

Loading chart…

The Hodgkin Lymphoma Treatment market is shaped by key forces such as technology shifts, regulations, and consumer behavior. The largest region in the market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare infrastructure and a rising patient population. As the industry continues to evolve, it is essential for stakeholders to stay informed about the latest trends and developments in the Hodgkin Lymphoma Treatment market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cell Medica Limited; Cellular Biomedicine Group, Inc.; Constellation Pharmaceuticals, Inc.; Curis, Inc.; Faron Pharmaceuticals Oy; Fate Therapeutics, Inc.; Gamida Cell Ltd.; Gilead Sciences, Inc.; Incyte Corporation; Merck & Co., Inc.; Mirati Therapeutics Inc.; Molecular Templates Inc.; NantKwest, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hodgkin Lymphoma Treatment market is poised for significant growth, driven by various factors. The market dynamics can be understood by analyzing the growth drivers, restraints, opportunities, and challenges that shape the industry.

Growth Drivers2 items

Increasing Hodgkin Lymphoma Treatment market size due to the rising prevalence of Hodgkin lymphoma, particularly among the younger population, is expected to fuel the demand for effective treatments, thereby driving the market growth forecast.

Advancements in immunotherapy and targeted therapies have improved treatment outcomes, leading to increased adoption and driving the growth of the Hodgkin Lymphoma Treatment market.

Restraints2 items

High costs associated with Hodgkin Lymphoma Treatment, particularly for newer therapies, can limit access to treatment, thereby restraining market growth and affecting the overall growth forecast.

Stringent regulatory requirements and the need for extensive clinical trials can delay the approval and launch of new treatments, hindering the growth of the Hodgkin Lymphoma Treatment market size.

Opportunities2 items

Emerging markets, particularly in Asia-Pacific and Latin America, offer significant opportunities for growth due to increasing healthcare spending and improving healthcare infrastructure, which can contribute to the Hodgkin Lymphoma Treatment market expansion.

The development of personalized medicine and biomarker-based treatments can provide new avenues for growth in the Hodgkin Lymphoma Treatment market, enabling more effective and targeted therapies.

Challenges2 items

The Hodgkin Lymphoma Treatment market faces challenges related to the patent expiration of key therapies, which can lead to increased competition from generic versions and impact market revenue.

Managing the side effects of treatments and improving patient outcomes while reducing healthcare costs are significant challenges that need to be addressed to ensure sustainable growth of the Hodgkin Lymphoma Treatment market size and improve the overall growth forecast.

Market Segmentation

Loading chart…

The Type segment in the Hodgkin Lymphoma Treatment market refers to the different classes of therapies used to treat the disease. This includes chemotherapy, radiation therapy, targeted therapy, and immunotherapy, among others. Each type of treatment has its own set of benefits and drawbacks, and the choice of treatment depends on the stage and severity of the disease. Understanding the Hodgkin Lymphoma Treatment segmentation by type is crucial in determining the market size and potential for growth.

The Application segment in the Hodgkin Lymphoma Treatment market is categorized based on the subtypes of the disease, such as classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Each subtype has distinct characteristics and requires specific treatment approaches. The application segment helps in identifying the most common subtypes of the disease and the corresponding treatment options, thereby contributing to the overall market size. The market taxonomy of Hodgkin Lymphoma Treatment is complex, and analyzing the application segment is essential for understanding the dynamics of the market.

Hodgkin Lymphoma Treatment Segmentation Breakdown11 items

Type

/> Alocrest

ANK Program

Azacitidine

BMS-986016

BPX-501

Others

Application

/> Hospital

Clinic

Research Center

Regional Insights

Loading chart…

The Hodgkin Lymphoma Treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of advanced treatments, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include policies supporting cancer research, a strong ecosystem, and significant investments in healthcare. Asia Pacific is driven by growing adoption, increasing infrastructure development, and favorable policies. Latin America and Middle East & Africa are driven by growing demographics, increasing adoption, and improving infrastructure.

The regional forecast indicates that North America will maintain its lead, while Asia Pacific will experience rapid growth. Europe will remain a significant contributor, driven by its mature ecosystem and strong policies. Latin America and Middle East & Africa will experience steady growth, driven by increasing adoption and improving infrastructure.

Competitive Landscape

The Hodgkin Lymphoma Treatment market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, and product innovation. Regulatory approvals and certifications also play a crucial role in the Hodgkin Lymphoma Treatment competitive landscape. Global players tend to dominate the market, but local companies are gaining ground through strategic partnerships and regional expansion.

Key players in the market employ various strategies to differentiate themselves, including technology, service model, and channel strength. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. Companies are focusing on innovation pipelines, regional expansion, and premium pricing to stay competitive. The following companies are notable for their strategic focus:

Cell Medica Limited: innovation pipeline

Constellation Pharmaceuticals, Inc.: premium pricing

Curis, Inc.: regional expansion

Fate Therapeutics, Inc.: OEM tie-ups

Gilead Sciences, Inc.: vertical integration

Incyte Corporation: local manufacturing

Key Hodgkin Lymphoma Treatment Companies13 items

Cell Medica Limited

Cellular Biomedicine Group, Inc.

Constellation Pharmaceuticals, Inc.

Curis, Inc.

Faron Pharmaceuticals Oy

Fate Therapeutics, Inc.

Gamida Cell Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Merck & Co., Inc.

Mirati Therapeutics Inc.

Molecular Templates Inc.

NantKwest, Inc.

Market Ecosystem

The Hodgkin Lymphoma Treatment ecosystem spans across upstream, midstream, and downstream segments, involving various stakeholders who create and capture value. Upstream participants, such as technology providers and suppliers, provide essential components and innovations. Midstream integrators and channels facilitate the development and distribution of treatments, while downstream end users, including healthcare providers and patients, ultimately receive and administer these treatments. Understanding the Hodgkin Lymphoma Treatment ecosystem requires a comprehensive value chain analysis.

Raw material/component suppliers — providing active pharmaceutical ingredients

OEMs / manufacturers — producing treatments and therapies

Technology providers — developing innovative treatments and diagnostic tools

System integrators / EPCs — integrating treatments into healthcare systems

Distributors / channel partners — delivering treatments to healthcare providers

Regulators/standards bodies — overseeing treatment approvals and compliance

End users / buyers — healthcare providers and patients receiving treatments

The flow of value within the Hodgkin Lymphoma Treatment ecosystem is influenced by control points, such as regulatory approvals and reimbursement decisions, which can impact the adoption of new treatments. Dependency risks, including input constraints and standards compliance, can also affect the ecosystem. Moreover, switching costs, partnerships, and interoperability requirements may vary across different regions, leading to diverse ecosystem dynamics. As a result, understanding these factors is crucial for navigating the complexities of the Hodgkin Lymphoma Treatment ecosystem.

Recent Industry Insights

The Hodgkin Lymphoma Treatment industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships have focused on enhancing treatment options, with companies collaborating to develop innovative therapies. Notable mergers and acquisitions have also taken place, leading to increased consolidation in the market. Furthermore, several product and technology launches have expanded the treatment landscape, offering improved outcomes for patients. Regulatory changes have also played a crucial role, with updates to treatment guidelines and approvals of new therapies. A shift in consumer trends has been observed, with a growing emphasis on personalized medicine and targeted therapies. Additionally, funding rounds and expansions have supported the development of novel treatments, driving growth in the Hodgkin Lymphoma Treatment market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Hodgkin Lymphoma Treatment market outlook. The market attractiveness is moderate, driven by increasing incidence rates and advancements in treatment options. Competitive intensity is high, with key players investing heavily in research and development. The long-term outlook is promising, with a growing demand for targeted therapies and immunotherapies.

The innovation landscape is rapidly evolving, with a focus on personalized medicine and combination therapies. However, the demand-supply balance is a concern, with a shortage of skilled healthcare professionals and high treatment costs. Key risk factors include regulatory challenges, patent expirations, and intense competition. Overall, the Hodgkin Lymphoma Treatment market is expected to experience steady growth, driven by advancements in treatment options and increasing patient awareness.

11 items

1. Executive Summary

2. Hodgkin Lymphoma Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hodgkin Lymphoma Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hodgkin Lymphoma Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Alocrest

6.1.2. ANK Program

6.1.3. Azacitidine

6.1.4. BMS-986016

6.1.5. BPX-501

6.1.6. Others

6.2. Global Hodgkin Lymphoma Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Clinic

6.2.3. Research Center

6.3. Global Hodgkin Lymphoma Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hodgkin Lymphoma Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hodgkin Lymphoma Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Hodgkin Lymphoma Treatment Market Competition by Key Manufacturers

8.1. Global Hodgkin Lymphoma Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hodgkin Lymphoma Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Cell Medica Limited

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cellular Biomedicine Group, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Constellation Pharmaceuticals, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Curis, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Faron Pharmaceuticals Oy

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fate Therapeutics, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Gamida Cell Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Gilead Sciences, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Incyte Corporation

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Merck & Co., Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Mirati Therapeutics Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Molecular Templates Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. NantKwest, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hodgkin Lymphoma Treatment Market

Figure 4: Global Hodgkin Lymphoma Treatment Market: Drivers

Figure 5: Global Hodgkin Lymphoma Treatment Market: Challenges

Figure 6: Global Hodgkin Lymphoma Treatment Market: Trends

Figure 7: Global Hodgkin Lymphoma Treatment Market: Opportunity

Figure 8: Global Hodgkin Lymphoma Treatment Market: Restraint

Figure 9: Global Hodgkin Lymphoma Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Hodgkin Lymphoma Treatment Market Value (USD Million) By Region

Figure 15: Global Hodgkin Lymphoma Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Hodgkin Lymphoma Treatment Market Value (USD Million) By Region

Figure 23: Global Hodgkin Lymphoma Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Hodgkin Lymphoma Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Hodgkin Lymphoma Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Hodgkin Lymphoma Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Hodgkin Lymphoma Treatment Market Value (USD Million) By Region

Table 10: Global Hodgkin Lymphoma Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Hodgkin Lymphoma Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hodgkin Lymphoma Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hodgkin Lymphoma Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Cell Medica Limited Basic Information And Sales Area

Table 31: Cell Medica Limited. Products Portfolio

Table 32: Cellular Biomedicine Group, Inc. Basic Information And Sales Area

Table 33: Cellular Biomedicine Group, Inc.. Products Portfolio

Table 34: Constellation Pharmaceuticals, Inc. Basic Information And Sales Area

Table 35: Constellation Pharmaceuticals, Inc.. Products Portfolio

Table 36: Curis, Inc. Basic Information And Sales Area

Table 37: Curis, Inc.. Products Portfolio

Table 38: Faron Pharmaceuticals Oy Basic Information And Sales Area

Table 39: Faron Pharmaceuticals Oy. Products Portfolio

Table 40: Fate Therapeutics, Inc. Basic Information And Sales Area

Table 41: Fate Therapeutics, Inc.. Products Portfolio

Table 42: Gamida Cell Ltd. Basic Information And Sales Area

Table 43: Gamida Cell Ltd.. Products Portfolio

Table 44: Gilead Sciences, Inc. Basic Information And Sales Area

Table 45: Gilead Sciences, Inc.. Products Portfolio

Table 46: Incyte Corporation Basic Information And Sales Area

Table 47: Incyte Corporation. Products Portfolio

Table 48: Merck & Co., Inc. Basic Information And Sales Area

Table 49: Merck & Co., Inc.. Products Portfolio

Table 50: Mirati Therapeutics Inc. Basic Information And Sales Area

Table 51: Mirati Therapeutics Inc.. Products Portfolio

Table 52: Molecular Templates Inc. Basic Information And Sales Area

Table 53: Molecular Templates Inc.. Products Portfolio

Table 54: NantKwest, Inc. Basic Information And Sales Area

Table 55: NantKwest, Inc.. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Hodgkin Lymphoma Treatment Market Value (USD Million) By Region

Table 61: Global Hodgkin Lymphoma Treatment Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Type

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Type

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hodgkin Lymphoma Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Cell Medica Limited; Cellular Biomedicine Group, Inc.; Constellation Pharmaceuticals, Inc.; Curis, Inc.; Faron Pharmaceuticals Oy; Fate Therapeutics, Inc.; Gamida Cell Ltd.; Gilead Sciences, Inc.; Incyte Corporation; Merck & Co., Inc.; Mirati Therapeutics Inc.; Molecular Templates Inc.; NantKwest, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options